134 related articles for article (PubMed ID: 38307551)
1. Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer.
Check JH; Check DL; DO TP; Srivastava M; Check E
Anticancer Res; 2024 Feb; 44(2):659-664. PubMed ID: 38307551
[TBL] [Abstract][Full Text] [Related]
2. The role of progesterone and the progesterone receptor in cancer: progress in the last 5 years.
Check JH; Check DL
Expert Rev Endocrinol Metab; 2023 Jan; 18(1):5-18. PubMed ID: 36647582
[TBL] [Abstract][Full Text] [Related]
3. New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor.
Check JH; Check D
Anticancer Res; 2021 Dec; 41(12):5873-5880. PubMed ID: 34848442
[TBL] [Abstract][Full Text] [Related]
4. Palliative Benefits of Oral Mifepristone for the Treatment of Metastatic Fibroblastic Osteosarcoma.
Check JH; Check D; Poretta T; Wilson C
Anticancer Res; 2021 Apr; 41(4):2111-2115. PubMed ID: 33813421
[TBL] [Abstract][Full Text] [Related]
5. Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
Check JH; Check D; Poretta T
Anticancer Res; 2019 Apr; 39(4):1923-1926. PubMed ID: 30952734
[TBL] [Abstract][Full Text] [Related]
6. Evidence that Mifepristone, a progesterone receptor antagonist, can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV.
Check JH; Wilson C; Cohen R; Sarumi M
Anticancer Res; 2014 May; 34(5):2385-8. PubMed ID: 24778047
[TBL] [Abstract][Full Text] [Related]
7. Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity.
Check JH; Sansoucie L; Chern J; Amadi N; Srivastava M; Larece K
Clin Exp Obstet Gynecol; 2007; 34(4):207-11. PubMed ID: 18225679
[TBL] [Abstract][Full Text] [Related]
8. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract][Full Text] [Related]
9. Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.
Check JH; Check D; Wilson C; Lofberg P
Anticancer Res; 2016 Dec; 36(12):6511-6513. PubMed ID: 27919975
[TBL] [Abstract][Full Text] [Related]
10. Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life.
Check JH; Check D; Srivastava MD; Poretta T; Aikins JK
Anticancer Res; 2020 Dec; 40(12):6997-7001. PubMed ID: 33288594
[TBL] [Abstract][Full Text] [Related]
11. The progesterone receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of progesterone.
Check JH; DiAntonio G; DiAntonio A; Duroseau M
Clin Exp Obstet Gynecol; 2016; 43(2):189-91. PubMed ID: 27132407
[TBL] [Abstract][Full Text] [Related]
12. Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers - A Review.
Check JH; Check D
Anticancer Res; 2019 Jul; 39(7):3365-3372. PubMed ID: 31262857
[TBL] [Abstract][Full Text] [Related]
13. Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report.
Wang X; Liang J; Li L; Pan Z; Wang L
Anticancer Drugs; 2023 Feb; 34(2):306-310. PubMed ID: 36206142
[TBL] [Abstract][Full Text] [Related]
14. Support for the hypothesis that successful immunotherapy of various cancers can be achieved by inhibiting a progesterone associated immunomodulatory protein.
Check JH; Dix E; Sansoucie L
Med Hypotheses; 2009 Jan; 72(1):87-90. PubMed ID: 18842348
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.
Check JH; Dix E; Cohen R; Check D; Wilson C
Anticancer Res; 2010 Feb; 30(2):623-8. PubMed ID: 20332480
[TBL] [Abstract][Full Text] [Related]
16. Mifepristone causing complete remission of rapidly advancing leukemia with measurement of progesterone-induced blocking factor.
Check JH; Check D; Cohen R; Sarumi M
Anticancer Res; 2014 May; 34(5):2413-6. PubMed ID: 24778052
[TBL] [Abstract][Full Text] [Related]
17. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib.
Ren X; Cai X; Li J; Zhang X; Yu J; Song X; Zhang H; Song X
J Int Med Res; 2020 Jun; 48(6):300060520927918. PubMed ID: 32600081
[TBL] [Abstract][Full Text] [Related]
18. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
[TBL] [Abstract][Full Text] [Related]
19. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
Wahab A; Kesari K; Chaudhary S; Khan M; Khan H; Smith S; Boumber Y
Cancer Biol Ther; 2017 Dec; 18(12):940-943. PubMed ID: 29157085
[TBL] [Abstract][Full Text] [Related]
20. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
Shan CG; Wang H; Lin T; Liu D; Wen L; Chen ZJ; Zhen JJ; Lai MY; Zhang L; Zou X; Hong WP; Cai LB
Ann Palliat Med; 2021 May; 10(5):5897-5901. PubMed ID: 33977730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
